Next Science Ltd
ASX:NXS
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.125
0.47
|
Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one NXS stock under the Base Case scenario is 1.454 AUD. Compared to the current market price of 0.135 AUD, Next Science Ltd is Undervalued by 91%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Next Science Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for NXS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Next Science Ltd
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Next Science Ltd
Balance Sheet Decomposition
Next Science Ltd
Current Assets | 8.2m |
Cash & Short-Term Investments | 3.6m |
Receivables | 3.2m |
Other Current Assets | 1.3m |
Non-Current Assets | 3.6m |
PP&E | 1.3m |
Intangibles | 2.3m |
Other Non-Current Assets | 36.7k |
Current Liabilities | 3.8m |
Accounts Payable | 3.1m |
Accrued Liabilities | 132.4k |
Other Current Liabilities | 531k |
Non-Current Liabilities | 987.7k |
Long-Term Debt | 569k |
Other Non-Current Liabilities | 418.8k |
Earnings Waterfall
Next Science Ltd
Revenue
|
23.3m
USD
|
Cost of Revenue
|
-4.9m
USD
|
Gross Profit
|
18.4m
USD
|
Operating Expenses
|
-31.9m
USD
|
Operating Income
|
-13.6m
USD
|
Other Expenses
|
67.6k
USD
|
Net Income
|
-13.5m
USD
|
Free Cash Flow Analysis
Next Science Ltd
USD | |
Free Cash Flow | USD |
NXS Profitability Score
Profitability Due Diligence
Next Science Ltd's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Score
Next Science Ltd's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
NXS Solvency Score
Solvency Due Diligence
Next Science Ltd's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Score
Next Science Ltd's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NXS Price Targets Summary
Next Science Ltd
According to Wall Street analysts, the average 1-year price target for NXS is 0.275 AUD with a low forecast of 0.273 AUD and a high forecast of 0.284 AUD.
Dividends
Current shareholder yield for NXS is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
NXS Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Next Science Ltd. engages in the research, development, and distribution of technologies with bacterial issue application. The company is headquartered in Chatswood, New South Wales. The company went IPO on 2019-04-18. The firm's principal activities include development and commercialization of XBIO technology. The XBIO technology is a non-toxic technology used in solving the problems of bacterial biofilms. The firm's product includes XPERIENCE, SURGX, BACTISURE and BLASTX. The XPERIENCE product is an antimicrobial solution used to prevent surgical site infections by rinsing away debris and microorganisms. SURGX Sterile Antimicrobial Gel is used to reduce surgical site and post-surgical infections by destroying planktonic and biofilm-based bacteria within the gel. The BLASTX is an antimicrobial wound gel.
Contact
IPO
Employees
Officers
The intrinsic value of one NXS stock under the Base Case scenario is 1.454 AUD.
Compared to the current market price of 0.135 AUD, Next Science Ltd is Undervalued by 91%.